



WORLD ECONOMIC FORUM



Technology
Pioneer
2007

NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX: AMF

AMORFIX TO PRESENT AT WORKSHOP FOR vCJD DIAGNOSTIC ASSAYS HOSTED BY THE EUROPEAN COMMISSION

TORONTO, Ontario – September 20, 2007 – Amorfix Life Sciences (TSX: AMF), a company focused on diagnostics and treatments for brain-wasting diseases, today announced that it has been invited to present at a workshop on the common technical specifications (CTS) for variant Creutzfeldt-Jacob Disease (vCJD) diagnostic assays to be held on October 26 in Brussels, Belgium and sponsored by the Medical Device branch of the Enterprise and Industry Directorate-General of the European Commission.

“The European Commission’s workshop on vCJD diagnostic assays demonstrates progress towards the establishment of European Union (EU) regulations and the need for a viable vCJD blood screening test. We believe EU technical standards will serve to validate the importance of vCJD blood screening and encourage adoption among member states,” said Dr. George Adams, President & Chief Executive Officer of Amorfix. “We will attend as an industry expert and a developer of in vitro diagnostic medical devices. The opportunity to contribute to the regulatory process at this early stage is critical to ensuring an appropriate and high standard for vCJD diagnostic assays.”

The attendees of the workshop will present and discuss the current state of vCJD diagnostic development as well as the need to amend the current products under the CTS framework to include vCJD diagnostic devices. The workshop will also set up a subgroup to identify and recommend the necessary technical data needed to amend the CTS and establish guidelines for manufacturers and notified bodies. The vCJD workshop was scheduled under the sponsorship of the United Kingdom.

Common Technical Specifications

Originally developed in 1998, the CTS framework is a directive of the European Commission for EU-wide technical specifications for all regulated products. The objective of CTS is to replace existing national rules of individual members, which differ on a state by state basis, with one EU-wide standard that applies to each member state. From time to time Directive 98/79/EC(1) is updated with new in vitro medical device products to ensure conformity and a high level of health protection.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer’s Disease, Parkinson’s Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix’s proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated

misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- 30 -

For more information, please contact:

<p>Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3813 Fax: (416) 482-3811 george.adams@amorfix.com</p>	<p>James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3814 Fax: (416) 482-3811 james.parsons@amorfix.com</p>
--	--